MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient With Severe ARDS at ATS Annual Meeting
MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient With Severe ARDS at ATS Annual Meeting
NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced presentation of clinical data on agenT-797 in a complex case of severe acute respiratory distress (ARDS) at the American Thoracic Society (ATS) Annual Meeting. These translational and mechanistic insights build on an expanding dataset of clinical activity for patients with severe ARDS.
紐約，2024年5月22日（GLOBE NEWSWIRE）——MinK Therapeutics, Inc.（納斯達克股票代碼：INKT）是一家臨床階段的生物製藥公司，率先發現、開發和商業化治療癌症和其他免疫介導疾病的異基因、現成不變自然殺傷劑 T（inkT）細胞療法，今天宣佈公佈一例複雜病例中有關Agent-797的臨床數據在美國胸科學會（ATS）年會上討論嚴重急性呼吸窘迫（ARDS）。這些轉化與機制見解建立在不斷擴大的重度 ARDS 患者臨床活動數據集之上。
"Consistent with our prior publication of the survival benefit of agenT-797 in severe respiratory distress, the observed improvement in this case further demonstrates the potential of allogeneic iNKT cells in this setting," said Dr. Terese Hammond, University of California Los Angeles. "New therapeutic options, like allogeneic cell therapies, are urgently needed to address the critical unmet need in immune-compromised individuals with respiratory distress. I believe this growing body of data illuminates how iNKTs may have an impactful role in treating acute critical illness and merits further investigation."
加州大學洛杉磯分校的特蕾絲·哈蒙德博士說：“與我們先前發表的關於Agent-797在嚴重呼吸窘迫中的存活益處的出版物一致，在本例中觀察到的改善進一步表明了異體inKT細胞在這種環境中的潛力。”“迫切需要新的治療選擇，例如異基因細胞療法，來滿足免疫功能低下的呼吸窘迫患者未得到滿足的關鍵需求。我相信，越來越多的數據說明了INKTS如何在治療急性危重疾病方面發揮有影響力的作用，值得進一步研究。”
Clinical Findings
臨床發現
- Patient: A 26-year-old chronically immunosuppressed patient post-renal transplant contracted COVID-19 and progressed to severe hypoxemic respiratory failure, requiring veno-venous extracorporeal membrane oxygenation (VV-ECMO).
- Treatment: A single dose of 1x10^9 allogeneic iNKT cells (agenT-797) on hospital day 13.
-
Outcomes: Clinical changes showed a rapid decrease in inflammatory cytokines, including IL-18 following agenT-797 administration, consistent with the data observed in the Phase 1 trial of agenT-797 in COVID-19 ARDS (Hammond, T.C., Nat Commun 2024). The patient was extubated on day 37 and discharged home from the hospital on day 60, weaned off hemodialysis and returned to normal activities of daily living (ADLs) within 6 months of dosing.
- 患者：一名 26 歲的慢性免疫抑制患者在腎移植後感染了 COVID-19，進展爲嚴重的低氧血性呼吸衰竭，需要靜脈靜脈體外膜氧合 (VV-ECMO)。
- 治療：在住院第 13 天單劑量 1x10^9 個異體 inKT 細胞（Agent-797）。
- 結果：臨床變化顯示，在給藥 Agent-797 後，包括 IL-18 在內的炎症細胞因子迅速減少，這與 Agent-797 在 COVID-19 ARDS 中的 1 期試驗中觀察到的數據一致（哈蒙德，T.C. Nat Commun 2024）。患者在第37天被拔管，並在第60天出院回家，斷絕血液透析，並在給藥後的6個月內恢復正常的日常生活（ADL）。
The full poster presentation can be found on the Publications page of the MiNK website at https://minktherapeutics.com/publications/.
完整的海報演示文稿可以在MinK網站的出版物頁面上找到，網址爲 https://minktherapeutics.com/publications/。
About MiNK Therapeutics
關於 MinK Therapeut
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/ or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.
MinK Therapeutics是一家處於臨床階段的生物製藥公司，開創了用於治療癌症和其他免疫介導疾病的異基因不變自然殺傷T（InkT）細胞療法的發現、開發和商業化。MinK正在推進原生和下一代工程InkT程序的管道，其平台旨在促進可擴展和可重複的製造，以實現現成交付。該公司總部位於紐約州紐約。欲了解更多信息，請訪問 https://minktherapeutics.com/ 或者 @MiNK_iNKT。可能對投資者很重要的信息將定期發佈在我們的網站和社交媒體渠道上。
Forward Looking Statements
前瞻性陳述
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic and curative potential of agenT-797 and iNKT cells the mechanism of action, potency and safety, interim or top-line data, including statements regarding clinical data of agenT-797, the anticipated benefits of agenT-797 and clinical development plans and timelines. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These forward-looking statements are subject to risks and uncertainties, including the factors described under the Risk Factors section of the most recent Form 10-K filed with the SEC. MiNK cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and MiNK undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
本新聞稿包含根據聯邦證券法安全港條款做出的前瞻性陳述，包括有關Agent-797和inKT細胞的治療和治療潛力、作用機制、效力和安全性、中期或主要數據，包括有關Agent-797臨床數據、Agent-797的預期益處以及臨床開發計劃和時間表的聲明。這些前瞻性陳述受風險和不確定性的影響，可能導致實際結果出現重大差異。這些前瞻性陳述受風險和不確定性的影響，包括向美國證券交易委員會提交的最新10-K表中 “風險因素” 部分中描述的因素。MinK提醒投資者不要過分依賴本新聞稿中包含的前瞻性陳述。這些聲明僅代表截至本新聞稿發佈之日，除法律要求外，MinK沒有義務更新或修改聲明。本警示性陳述對所有前瞻性陳述進行了明確的完整限定。
Investor Contact
投資者聯繫人
917-362-1370
917-362-1370
Media Contact
媒體聯繫人
781-674-4428
781-674-4428
Source: MiNK Therapeutics
來源：MinK Therapeutics
譯文內容由第三人軟體翻譯。